Active surveillance — in which prostate cancer is regularly monitored for signs of progression — spares men whose tumors may never progress from potential treatment-associated adverse effects, such as sexual dysfunction or incontinence. Proponents contend active surveillance is a viable option because mortality rates among men whose tumors are limited to the prostate are low, and many of these men never experience symptoms from their disease. However, some urologic oncologists question active surveillance as a standard management strategy and contend its use should be limited. Read the article.
A new standard for evaluating MR images to diagnose prostate cancer has been agreed upon by international radiological institutions and is now published in the journal European Urology. The new procedure reduces the over-diagnosis of insignificant cancers by up to 89 percent and assists in the diagnosis of up to 13 percent more life-threatening tumors than current procedures. Read the article.
Incorporating scores from two urine-based biomarker assays may reduce the number of biopsies men with clinically localized prostate cancer need to undergo without greatly affecting 10-year survival rates, according to the results of a decision analysis. Read the article.
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have shown that the cells responsible for generating deadly prostate cancer share some genetic qualities with the tissue-specific stem cells that naturally reside in the healthy prostate. Read the article.
Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally advanced prostate cancer treated with radiotherapy. Read the article.
The addition of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial. Read the article.
Men with prostate cancer who also have had a heart attack may fare better with radiation therapy alone rather than with the standard treatment of radiation plus hormone therapy, a new analysis suggests. Over an average of 17 years of follow-up, men with high-risk prostate cancer who also had a heart condition lived longer after radiation treatment alone than similar men who had radiation and hormone therapy. Men who didn’t have heart problems lived longer if they had both treatments, the researchers added. Read the article.
A revolutionary prostate biopsy approach uses fewer needles and is more accurate for diagnosing prostate cancer. It is done during a real time MRI (magnetic resonance imaging) scan that clearly shows suspicious sites. When done by an expert radiologist using a highly powerful magnet, only a minimum number of needles are used to sample suspicious abnormalities. Read the article.
Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy
The study provides compelling evidence that few benign cancer suspicious regions increase in suspicion score and/or the greatest linear measurement within 1 year independent of the baseline suspicion score. Therefore, routinely repeating multiparametric magnetic resonance imaging at 1 year in men with pathologically benign cancer suspicious regions should be discouraged since it is unlikely to influence management decisions. Read the article.
High-dose-rate (HDR) brachytherapy was originally used with external beam radiation therapy (EBRT) to increase the dose to the prostate without injuring the bladder or rectum. Numerous studies have reported HDR brachytherapy is safe and effective. It has been adapted for use without EBRT for cases not requiring lymph node treatment. Read the article.